This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
First annual meeting of the network since it was transferred to ECDC in March 2010. Among the objectives of the meeting is to to present the epidemiological situation of diphtheria in Europe for 2009.